Leading the Way in Innovative Research for COVID-19 Patients

curncman
Posts: 821
Joined: Fri Jun 26, 2020 8:27 am

Physical therapy help with knee pain the lost book of remedies ebook

Post by curncman »

Physical therapy help with knee pain the lost book of remedies ebook



Physical therapy help with knee pain the lost book of remedies ebook
Here is the short answer If the knee pain is due to degenerative arthritis osteoarthritis, regenerative medicine can help. This co.nsists of stem cell therapy with added platelet rich plasma for activation of the stem cells. For knee arthritis the stem cells are typically a mix of mesenchymal stem cells from fay tissue and bone marrow stem cells from the pelvic bone. It may take 4 to 6 weeks after the stem cell therapy before the pain disappears, but then you are pain free. This beats all of the other methods of pain co.ntrol or anti inflammatory dru. You are using your own body stem cells to treat your arthritic co.ndition. Here is the long answer . reported about a man, Bill Marlette who had lost one of his arms in the past. He ended up overusing the other arm and as a result developed end stage osteoarthritis in his wrist. He could not find relief with co.nventional methods of anti inflammatories and pain pills. Next he went to a stem cell expert in Munich, Germany who treated him with mesenchymal stem cells from his fay tissue. Only one treatment took away his chronic pain and helped him regain his wrist mobility. Approval of stem cell therapy in Germany Prof. Dr. Eckhard Alt, an expert in regenerative medicine has previously treated patients with end stage osteoarthritis and had good clinical outcomes with it. As a result the German regulatory agency has approved his treatment protocol. Dr. David Pearce, executive vice president for research at Sanford Health in South Dakota said that Prof. Dr. Eckhard Alt was the first one to use fa.t cells as a source of mesenchymal stem cells to treat osteoarthritis. He went on to say Those stem cells dont have to be programmed in any way, but if you put them in the right environment, they will naturally turn into what the cell type around them is. The physician harvts the stem cells through liposuction. An enzyme mixture is necessary to separate the stem cells from fa.t cells, oil and co.nnective tissue. A cell separator can also help separating the stem cells from the rt of the cells and tissue. A case of wrist osteoarthritis As I mentioned before only one injection was necessary to relieve the chronic pain of Bill Marlettes wrist. Since his return the doctors in the US have followed Bill closely. They took MRI scans and noted that the bony cysts associated with the severe arthritis have disappeared. His wrist and hand strength have returned to normal. The pain almost disappeared. There were no side effects whatsoever. Because the stem cells are of the same tissue type as all his other cells of his body, one would not expect any tissue rejection by the immune system. Bill Marlette did not need any pain pills following the procedure in August 2016. And he says I have more range of motion with my wrist, shaking hands didnt hurt anymore, he said. My wrist seems to co.ntinue to improve, and theres less and less pain all the time. Past experiences treating osteoarthritis with mesenchymal stem cells A 2014 clinical trial from Korea involved 18 patients with osteoarthritis of the knee where adipose mesenchymal stem cells were injected. The high dose group did be. After 6 months there was significant improvement, also coirmed by arthroscopy. The previous cartilage defect in the femoral and tibial co.ndyles had decreased in size. Range of motion in the knee joints and pain had also improved. There were no adverse effects from the treatment. Chinese study Mesenchymal progenitor cells have the propensity to develop into cartilage. At the Shanghai Medical College, Fudan University Shanghai, China the following experiment took place in 2015 . The researchers grew human adipose mesenchymal cells in vitro. Later they injected these mesenchymal progenitor cells into the knees of rabbits with experimentally produced osteoarthritis. Despite doing xenotransplants human cartilage to rabbits with known HLA differences the cartilage grew and cured the osteoarthritis of the rabbits. The new cartilage had human HLA markers while the rabbit cartilage underneath had rabbit HLA markers. At 16 weeks the researchers examined the tissues under the microscope and another exam involved the HLA marker tting. Tehran study A study from Tehran, Iran was carried out on 18 patients with ankle, knee and hip osteoarthritis in 2015. Physicians injected stem cells from the bone marrow into the osteoarthritic joint. The doctors followed the patients and ordered occasional MRI scans for 30 months. All of the patients had improved significantly with regard to their joint function and pain. The MRI scans also showed thickening of the joint surfaces from new cartilage production. French/German study In a 2016 joint French/German study 18 patients with end stage knee osteoarthritis were treated with stem cells.
curncman
Posts: 821
Joined: Fri Jun 26, 2020 8:27 am

Traits of Highly Successful Researchers! | PhD Summit Paul Coffer, PhD & Simon Cook, PhD

Post by curncman »

Traits of Highly Successful Researchers! | PhD Summit Paul Coffer, PhD & Simon Cook, PhD



Speakers:
About Paul Coffer, PhD:
Paul Coffer studied Biochemistry at Oxford University. In 1991 he obtained his PhD from the Ludwig Institute for Cancer Research in London, UK. Here, in the lab of Prof. James Woodgett, he identified Protein Kinase B (PKB/c-akt), a novel player in intracellular signal transduction. He subsequently relocated to the Hubrecht Institute in Utrecht, The Netherlands. This postdoctoral research was involved in investigating the mechanisms by which hematopoietic cytokines can regulate gene expression through transcription factor phosphorylation. Hereafter he moved to the Department of Respiratory Medicine at the University Medical Centre Utrecht to initiate his own research group. During this period, work focused on studying the role of intracellular signal transduction pathways in regulating both the production and function of leukocytes.

In 2005 Paul Coffer was appointed Professor of Pediatric Immunology at the University Medical Centre Utrecht and moved to the Wilhelmina Children’s Hospital where he worked within the Department of Immunology. Here research was expanded to include study not only of hematopoietic stem cell function, but also mesenchymal stem cells. Furthermore, a new research line investigating the control of regulatory T cell (Treg) function was initiated. In 2011 he moved to the Department of Cell Biology at the University Medical Center Utrecht where he was appointed Professor of Stem Cell Biology. Current work in his research group is focused on applying this fundamental research to the study of cancer, autoimmunity and regenerative medicine. From 2013-2014 worked at the Memorial Sloan Kettering Cancer Center (New York, USA) as a visiting professor in the Rudensky Lab. From 2016 the Coffer Lab relocated to the Regenerative Medicine Center Utrecht where work continues to understand transcriptional regulation in cell biology and disease.

About Simon Cook, PhD:
Simon Cook’s group studies protein kinase signalling pathways, in particular the MAPKs, DYRKs and the mTOR pathway. Simon is interested in how these pathways are regulated and how they control cell fates such as cell survival or apoptosis, cell division or cell cycle arrest, differentiation or terminal senescence. He has published over 115 papers that have received more than 11,500 citations.

Simon became interested in Signal Transduction during his Biochemistry degree at Royal Holloway College, University of London. He did his PhD in Michael Wakelam’s laboratory at the University of Glasgow, studying signalling by Phospholipase-C and -D.

A chance meeting over a beer (several beers actually) at a conference led to his move in 1991 to Post-Doc with Frank McCormick at ONYX Pharmaceuticals in the San Francisco Bay Area where he studied the then emerging RAS-RAF-MEK-ERK1/2 pathway.

After his Post-Doc Simon stayed on at ONYX as a Staff Scientist, member of the RAS Group Steering Committee and Project Manager for the Inflammation Project. In 1997 he took a tenure track Group Leader post at the Babraham Institute.

From 2000-2006 he held a CRUK Senior Cancer Research Fellowship and is currently Head of the Signalling Programme. He also coordinates Knowledge Exchange and Commercialisation activities within the Institute. His hobbies include birdwatching, walking, reading, music, cinema and undermining the system from within.
curncman
Posts: 821
Joined: Fri Jun 26, 2020 8:27 am

Cells & Immunity Andrew Seber

Post by curncman »

Cells & Immunity Andrew Seber

curncman
Posts: 821
Joined: Fri Jun 26, 2020 8:27 am

Oxford scientists behind COVID-19 vaccine set for multimillion pound payday

Post by curncman »

Folks now u know about form 4 allotment of shares to Tim and Dr.Tom are peanuts and contributing so much savings to the company and its shareholders.

Oxford scientists behind COVID-19 vaccine set for 20 million pound payday .

https://uk.finance.yahoo.com/news/covid ... 02383.html
curncman
Posts: 821
Joined: Fri Jun 26, 2020 8:27 am

ImmunityBio Announces Single Prime hAd5 COVID-19 Vaccination Induces a 10-Fold Increase in T Cell Response Equivalent to

Post by curncman »

ImmunityBio Announces Single Prime hAd5 COVID-19 Vaccination Induces a 10-Fold Increase in T Cell Response Equivalent to T Cell Responses from Patients Previously Infected with SARS-CoV-2

https://finance.yahoo.com/news/immunity ... 00941.html




More content below
Thu, April 8, 2021, 6:30 PM


More content below

IBRX
-0.27%
Preliminary Phase 1b findings in participants receiving the dual antigen hAd5 S + N vaccine generated Th1 dominant S and N specific T cells after a single prime subcutaneous injection

The magnitude of this T cell response was equivalent to those seen for S & N T cell responses from previously infected convalescent SARS-CoV-2 patients

These findings provide the potential of the hAd5 S + N T cell vaccine for use as a "Universal T Cell Booster" to enhance T cell immunity in healthy recipients of current vaccines or in previously infected convalescent subjects

Phase 1b study ongoing to explore the safety and immunogenicity of subcutaneous, oral and sublingual prime boost combinations of hAd5 S + N vaccine
Post Reply